



Building Better Biologics™

Zymeworks Receives LifeSciences BC Life Sciences Company of the Year Award

February 25, 2016

Vancouver, Canada – Zymeworks Inc. today announced that it has been awarded the 2016 Life Sciences Company of the Year Award by LifeSciences British Columbia. The award is presented annually to a company operating in the British Columbia life sciences sector whose accomplishments stood out through strong overall performance in the previous year. The award will be presented at the 18th Annual LifeSciences BC awards dinner on April 21, 2016.

“2015 was an exceptional year for Zymeworks, and we are deeply honoured to receive this year’s Life Sciences Company of the Year Award from LifeSciences BC,” said Dr. Ali Tehrani, President and CEO of Zymeworks. “In 2015 we announced new collaboration and licensing deals with Celgene and GSK, announced equity investments by our strategic partners Eli Lilly and Celgene, and entered into a strategic investment and merger agreement with an outstanding BC biotech company, Kairos Therapeutics. Our lead programs, ZW25 and ZW33, were advanced towards target IND dates in 2016, and we closed out the year by setting the stage for a CA\$86M (US\$61.5M) mezzanine financing, which we announced in January.”

“We enter 2016 poised to become a clinical-stage biopharmaceutical company as our pipeline of Azymetric™ therapeutic candidates begins to enter clinical trials targeting a variety of solid tumours with high unmet medical needs. We could not have reached this stage without our incredibly committed Zymeworks team, or without the strong and stable support of our shareholders, our board of directors, and our pharmaceutical and biotechnology partners Eli Lilly, Celgene, Merck, and GSK.”

About Zymeworks Inc.

Zymeworks is a privately held biotherapeutics company that is developing best-in-class Azymetric™ bi-specific antibodies and antibody drug conjugates for the treatment of cancer, autoimmune and inflammatory diseases. The company’s novel Azymetric™, AlbuCORE™, and EFECT™ platforms, and its proprietary ZymeCAD™ structure-guided protein engineering technology, enable the development of highly potent bi-specific antibodies and multivalent protein therapeutics across a range of indications. Zymeworks is focused on accelerating its preclinical biotherapeutics pipeline through in-house research and development programs and strategic collaborations.

Contact

Zymeworks Inc.

David Poon, Ph.D.

Executive Director, External R&D and Alliances

bd@zymeworks.com

(604) 678-1388

Media Inquiries

Michael Lampe

michael@michaellampeconsulting.com

(484) 575-5040